Clinical Research Directory
Browse clinical research sites, groups, and studies.
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
Sponsor: Oruka Therapeutics, Inc.
Summary
This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.
Official title: Phase 1, First-in-human, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-05-19
Completion Date
2027-01
Last Updated
2025-09-26
Healthy Volunteers
Yes
Conditions
Interventions
ORKA-002
ORKA-002 is supplied as sterile solution to be administered by SC injection
Placebo
Placebo solution to be administered at a matching volume by SC injection
Locations (1)
Oruka Therapeutics Investigative Site
Christchurch, New Zealand, New Zealand